secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2025-06-24T23:59:59+00:00
Accession:  0001193125-25-145242
Event type: debt
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines secures up to $2B financing from Royalty Pharma, withdraws cash runway guidance
--------------------------------------------------------------------------------

- Received $250M upfront from Royalty Pharma; up to $1.25B total synthetic royalty on daraxonrasib sales.
- Loan facility of up to $750M senior secured term loan (SOFR+5.75%, 3.50% floor), interest-only, matures by 2032.
- Additional tranches tied to daraxonrasib approval milestones; company retains global commercialization control.
- Withdraws prior cash runway end date and 2025 GAAP net loss guidance; expects updated guidance in Q2 2025 earnings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312525145242/0001193125-25-145242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312525145242/d838043d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-145242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer